semaglutide alzheimer's disease clinical trial alzheimer Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic (evoke and evoke+): two phase 3, randomised, placebo-controlled trials A Critical Appraisal of the

We conduct thorough assessments, including blood tests and physical exams, to ensure the well-being of our patients on semaglutide

Zhao S, Torres A, Henry RA, Trefely S, Wallace M, Lee JV, et al

Evidence classification indicated that one outcome was Class II (6%), three outcome was Class III (18%), five were Class IV (29%), and the rest were NS

Cons: Higher risk of initial stomach upset

The results demonstrated that patients who had previously received GLP-1RA treatment had a more favorable response to intravitreal injections, with improved visual acuity outcomes and reduced central retinal thickness

& Marioni, J